Autoantibodies: Pathogenic or epiphenomenon

Best Pract Res Clin Rheumatol. 2022 Jun;36(2):101767. doi: 10.1016/j.berh.2022.101767. Epub 2022 Jul 7.

Abstract

Idiopathic inflammatory myopathies (IIM) are heterogeneous autoimmune diseases. There are distinct subgroups, including antisynthetase syndrome, dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and sporadic inclusion body myositis. In patients with IIM, autoantibodies are present in up to 80% of the patients. These autoantibodies are often characterized as myositis-specific autoantibodies (MSA) or myositis-associated autoantibodies (MAA). The recognition of the importance of autoantibodies, especially MSA, is increasing in recent years. In this chapter, we provide an overview of the MSAs, including some new autoantibodies of interest as they target mainly muscle-specific autoantigen, in clinical classification, the measurement of the disease activity, and a possible role in the pathogenesis in the patients with IIM.

Keywords: Autoantibodies; Autoantigens; Myositis; Pathogenesis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies
  • Autoantigens
  • Autoimmune Diseases*
  • Dermatomyositis*
  • Humans
  • Myositis*
  • Myositis, Inclusion Body*

Substances

  • Autoantibodies
  • Autoantigens